Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Prospect Capital Corporation (PSEC) Price & Performance

Novartis AGTrade
Prospect Capital CorporationTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Prospect Capital Corporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Prospect Capital Corporation trades at $2.17 (market cap $1.12B). The key difference: Novartis AG is far larger — about 259.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.42%). Which is the better fit depends on your goals.

NVSPSEC
Market Cap
$290.25B$1.12B
Sector
HealthFinancials
52-Week High
$168.62$3.47
52-Week Low
$113.50$2.15
Enterprise Value
$330.27B
Dividend Yield
3.17%22.42%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

Read more on PSEC